Manzo J, Puhalla S, Pahuja S, Ding F, et al. A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. Cancer Chemother Pharmacol 2022 Apr 18. pii: 10.1007/s00280-022-04430.
PMID: 35435472